FY2026 EPS Estimates for Celcuity Increased by HC Wainwright

Celcuity, Inc. (NASDAQ:CELC) – Research analysts at HC Wainwright increased their FY2026 earnings per share (EPS) estimates for shares of Celcuity in a research note issued to investors on Wednesday, October 22nd. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($4.06) for the year, up from their prior forecast of ($4.15). HC Wainwright has a “Buy” rating and a $77.00 price target on the stock. The consensus estimate for Celcuity’s current full-year earnings is ($2.62) per share. HC Wainwright also issued estimates for Celcuity’s FY2027 earnings at $1.36 EPS, FY2028 earnings at $4.84 EPS and FY2029 earnings at $8.18 EPS.

CELC has been the topic of a number of other reports. Wall Street Zen lowered Celcuity from a “hold” rating to a “sell” rating in a research report on Sunday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celcuity in a research report on Friday. Needham & Company LLC set a $95.00 price objective on Celcuity in a research report on Monday, October 20th. Guggenheim began coverage on Celcuity in a research report on Monday, September 22nd. They issued a “buy” rating on the stock. Finally, Stifel Nicolaus assumed coverage on Celcuity in a research report on Tuesday, July 1st. They issued a “buy” rating and a $30.00 price target on the stock. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $65.50.

Celcuity Stock Up 0.6%

Shares of CELC opened at $70.97 on Friday. The firm has a market capitalization of $3.01 billion, a price-to-earnings ratio of -20.57 and a beta of 0.70. The company has a debt-to-equity ratio of 2.24, a quick ratio of 4.58 and a current ratio of 4.58. The business’s fifty day moving average price is $53.66 and its two-hundred day moving average price is $29.67. Celcuity has a 52 week low of $7.57 and a 52 week high of $83.00.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.14).

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Tema Etfs LLC lifted its holdings in Celcuity by 51.6% during the third quarter. Tema Etfs LLC now owns 25,790 shares of the company’s stock worth $1,274,000 after acquiring an additional 8,779 shares in the last quarter. Nisa Investment Advisors LLC lifted its holdings in Celcuity by 2,142.0% during the third quarter. Nisa Investment Advisors LLC now owns 15,627 shares of the company’s stock worth $772,000 after acquiring an additional 14,930 shares in the last quarter. Avanza Fonder AB bought a new position in Celcuity during the third quarter worth about $79,000. Harbor Capital Advisors Inc. bought a new position in Celcuity during the third quarter worth about $399,000. Finally, Red Door Wealth Management LLC bought a new position in Celcuity during the third quarter worth about $389,000. 63.33% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director David Dalvey sold 100,000 shares of the firm’s stock in a transaction on Monday, July 28th. The stock was sold at an average price of $43.98, for a total value of $4,398,000.00. Following the transaction, the director directly owned 125,000 shares in the company, valued at $5,497,500. This trade represents a 44.44% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 15.77% of the stock is owned by corporate insiders.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.